Sharma S J, Klussmann J P, Döscher J, Hoffmann T K, Laban S
Medizinische Fakultät, Klinik für Hals‑, Nasen‑, Ohrenheilkunde, Kopf- und Halschirurgie, Universitätsklinik zu Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
Center for Molecular Medicine Cologne (CMMC), Medizinische Fakultät, Universität zu Köln, Universitätsklinik zu Köln, Köln, Deutschland.
HNO. 2024 Dec;72(12):843-849. doi: 10.1007/s00106-024-01525-9. Epub 2024 Oct 25.
Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is becoming increasingly important in head and neck oncology. At this year's conference of the American Society of Clinical Oncology (ASCO), a large number of papers were presented on the topic of HPV-associated HNSCC, particularly with regard to neoadjuvant treatment approaches, radiation de-escalation strategies, therapeutic vaccines, and treatment monitoring. In this context, study results on the treatment of HPV-related recurrent respiratory papillomatosis (RRP) were also presented.
Based on contributions to the 2024 ASCO Annual Meeting, an insight into the latest developments in HPV-associated diseases of the head and neck is provided.
The papers were reviewed for clinical relevance and contextualized based on current therapeutic concepts.
A large number of studies on liquid biopsies (LB) were presented. It was shown that although the methods for analyzing LBs for HPV-positive patients are well developed and can be used for diagnostics, risk classification, treatment management, or tumor follow-up, the methods vary considerably, and their clinical application has not yet been sufficiently validated. With regard to therapeutic HPV vaccination, three large studies were presented for the treatment of recurrent/metastatic HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). The only randomized study was on the vaccine ISA101b (peltopepimut-S) and did not reach its primary endpoint; however, the vaccine seemed to be highly effective in patients with a combined positive score (CPS) ≥ 20. Furthermore, data from a phase I study on PRGN2012, an adenovirus-based immunotherapy used therapeutically for the treatment of recurrent respiratory papillomatosis (RRP), were presented. PRGN2012 led to a reduction in surgical interventions for RRP, and the US Food and Drug Administration (FDA) designated PRGN2012 as a breakthrough therapy and orphan drug. However, the vaccine is not yet approved for the treatment of RRP.
人乳头瘤病毒（HPV）相关的头颈部鳞状细胞癌（HNSCC）在头颈部肿瘤学中变得越来越重要。在今年的美国临床肿瘤学会（ASCO）会议上，发表了大量关于HPV相关HNSCC主题的论文，特别是在新辅助治疗方法、放疗降阶梯策略、治疗性疫苗和治疗监测方面。在此背景下，还展示了关于HPV相关复发性呼吸道乳头状瘤病（RRP）治疗的研究结果。
基于对2024年ASCO年会的贡献，深入了解HPV相关头颈部疾病的最新进展。
对这些论文进行临床相关性审查，并根据当前治疗概念进行背景分析。
展示了大量关于液体活检（LB）的研究。结果表明，虽然分析HPV阳性患者液体活检的方法已经很成熟，可用于诊断、风险分类、治疗管理或肿瘤随访，但这些方法差异很大，其临床应用尚未得到充分验证。关于治疗性HPV疫苗，展示了三项用于治疗复发性/转移性HPV阳性口咽鳞状细胞癌（OPSCC）的大型研究。唯一的随机研究是关于疫苗ISA101b（peltopepimut-S），未达到其主要终点；然而，该疫苗在综合阳性评分（CPS）≥20的患者中似乎非常有效。此外，还展示了一项关于PRGN2012的I期研究数据，PRGN2012是一种用于治疗复发性呼吸道乳头状瘤病（RRP）的腺病毒免疫疗法。PRGN2012减少了RRP的手术干预次数，美国食品药品监督管理局（FDA）将PRGN2012指定为突破性疗法和孤儿药。然而，该疫苗尚未被批准用于治疗RRP。
